Biodesix Inc reports results for the quarter ended June 30 - Earnings Summary

Biodesix

05/08/2026 22:01

Biodesix Inc BDSX.OQ reported a quarterly adjusted loss of 71 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.60.  The mean expectation of seven analysts for the quarter was for a loss of 90 cents per share. Wall Street expected results to range from $-1.05 to -81 cents per share.
Revenue rose 34.2% to $26.86 million from a year ago; analysts expected $26.03 million. 
Biodesix Inc's reported EPS for the quarter was a loss of 71 cents​.
The company reported a quarterly loss of $7.27 million.
Biodesix Inc shares had risen by 0.9% this quarter and gained 234.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 2.1% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is also "buy" 
Wall Street's median 12-month price target for Biodesix Inc is $28.50, about 20.2% above its last closing price of $22.76
This summary was machine generated from LSEG data August 5 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.90
-0.71
Beat
Mar. 31 2026 
-1.10
-0.81
Beat
Dec. 31 2025 
-0.85
-0.49
Beat
Sep. 30 2025 
-1.44
-1.16
Beat